Genetic mutations may impact cancer treatment



Turns out, genetic mutations in are distinct from those found in colon and that mutations in the genes are good predictors of survival among people with

To understand why some patients with cancer respond to standard treatment while others do not, researchers at the University of performed genetic profiling on appendiceal to compare mutations present in both cancer types.


“For that are rare like appendix cancer, obtaining molecular profiles will help identify potential treatment options since we don’t have the clinical trial data to help guide treatments as we do in common tumors,” said

The retrospective study found that is comprised of five distinct subtypes- (46 percent), (30 percent), (12 percent), (7.7 percent) and (5.2 percent).

A in the gene GNAS, rare in colon cancer, was found to be quite frequent in appendix cancer, especially in (52 percent) and (72 percent). Patients with harboring a GNAS had a median survival of almost 10 years, while those whose tumors had a TP53 had a median survival of only three years.

Understanding the molecular differences between the subtypes of is an important stepping stone for future clinical trials to develop and test different therapeutic approaches that are specific to this

The findings of the study published in the Journal of JCO Precision

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)



Source link